A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
NCT ID: NCT02177110
Last Updated: 2020-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
16 participants
OBSERVATIONAL
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Following treatment the elimination of cancer cells ultimately occurs by the activation of apoptotic cell death pathways. The SYS-ACT approach builds on a combination of mathematical systems of modelling, quantitative biochemistry and cell biology, and specifically predicts the drug responsiveness of melanoma cell lines to various apoptosis-inducing treatments.
The investigators propose to validate the SYS-ACT approach and application in a translational systems medicine study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study
Patients who have fresh frozen and FFPE tissue taken prior to treatment
No interventions assigned to this group
Control
Fresh frozen tissue and FFPE tissue is available
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient must be able to give own signed informed consent.
3. Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
4. Patients that are planned to receive either:
* Adjuvant treatment
* 1st line treatment for metastatic disease
* 2nd line treatment for metastatic disease
5. Patients with prior adjuvant treatment are allowed.
6. Patients receiving planned standard treatment of one or more of the following:
* Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
* Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
* BRAF and/or MEK inhibitors
7. Patients were FFPE and fresh frozen tissue is available (both mandatory).
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Trials Ireland
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cork University Hospital
Cork, , Ireland
Beaumont Hosptial
Dublin, , Ireland
Mater Misericordiae University Hospital and Mater Private Hospital
Dublin, , Ireland
St Vincent's University Hospital
Dublin, , Ireland
Galway University Hospital
Galway, , Ireland
Waterford Regional Hospital
Waterford, , Ireland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICORG 13-22
Identifier Type: -
Identifier Source: org_study_id